<DOC>
	<DOCNO>NCT00081640</DOCNO>
	<brief_summary>PRO 2000 Gel design inserted vagina protect woman get HIV sex . So far , PRO 2000 Gel test safety 136 woman Europe United States . This study evaluate safety acceptability PRO 2000 Gel use woman Pune , India . The study also examine Indian woman men think use PRO 2000 Gel .</brief_summary>
	<brief_title>Safety Acceptability PRO 2000 Vaginal Gel HIV Uninfected Women India</brief_title>
	<detailed_description>Topical microbicides design prevent sexual transmission HIV disease pathogen . PRO 2000/5 Gel ( P ) , PRO 2000 , vaginal microbicide evaluate Phase I safety trial Europe U.S . PRO 2000 Gel easily manufacture , highly stable , highly water-soluble . The aqueous gel formulation contain synthetic carbomer , lactic acid/lactate buffer , preservative . In vitro , PRO 2000 Gel show suppress infection herpes virus , Chlamydia trachomatis , Neisseria gonorrhoeae , wide range HIV-1 isolate . This study evaluate safety acceptability PRO 2000 Gel HIV uninfected woman Pune , India . The study precursor large Phase II/III study PRO 2000 Gel . Participants study sexually active HIV uninfected woman either low high risk HIV infection . Male partner woman also enrol study . Participants ask apply PRO 2000 Gel twice day 14 consecutive day menses vaginal intercourse single male partner , use study-provided male condom , least twice per week two week PRO 2000 Gel use . Participants screen visit , enrollment visit , 3 study visit two week PRO 2000 Gel use ; visit last 1 hour . Study visit include medical history , gynecologic exam , blood urine test , product acceptability questionnaire . Colposcopy perform three time study . Participants also ask complete Daily Study Record product use sexual activity questionnaire willingness use product perception product . Four week use PRO 2000 Gel , participant ask participate focus group discuss product acceptability . Participants ' male partner also ask participate focus group product use .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Inclusion Criteria All Female Participants : Age 18 45 HIV uninfected Regular menstrual cycle least 21 day menstrual cycle longacting progestin use No change hormonal contraceptive use 3 month prior study entry Agree use acceptable method contraception study Normal Pap smear screen 3 month prior study entry Sexually active single male sexual partner eligible study Agree abstain sexual intercourse 48 hour enrollment visit Willing complete Daily Study Records Agree follow study direction PRO 2000 Gel use sexual activity study Additional Inclusion Criteria Female Participants Higher Risk HIV Infection : Sexually transmit disease ( STD ) 3 month prior study entry Current male partner STD 3 month prior study entry Inclusion Criteria Male Partners Female Participants : Age 18 year old HIV uninfected No STD symptom study entry Agree abstain sexual intercourse 48 hour enrollment visit Agree vaginal intercourse partner take part study Agree vaginal intercourse least twice week study use study provide male condom Exclusion Criteria All Female Participants : Menopausal Breastfeeding Used nontherapeutic intravenous drug within 1 year study Currently pregnant pregnant 3 month prior study entry Serious liver , kidney , blood abnormality Urinary tract infection determine positive urine culture Genital abnormality History adverse reaction anticoagulant History sensitivity allergy latex Used spermicide spermicidally lubricate condom week prior study entry Participated investigational drug trial 30 day prior study entry Used intrauterine contraceptive device 3 month prior study entry Abnormal Pap smear 3 month prior study entry Gynecological surgery 3 month prior study entry Breakthrough menstrual bleed 3 month prior study entry Vaginal bleeding follow intercourse 3 month prior study entry Additional Exclusion Criteria Female Participants Low Risk HIV Infection : STD pelvic inflammatory disease 3 month prior study entry Current male partner STD 3 month prior study entry Current male partner inject nontherapeutic drug 3 month prior study entry Signs pelvic exam consistent STD bacterial vaginosis Exclusion Criteria Male Partners Female Participants History adverse reaction latex Refuse examination treatment STD STD symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Vaginal Microbicide</keyword>
</DOC>